Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas

Cancer Treat Res. 1997:91:189-203. doi: 10.1007/978-1-4615-6121-7_13.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Chemotherapy, Cancer, Regional Perfusion* / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Extremities
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sarcoma / drug therapy
  • Sarcoma / mortality
  • Sarcoma / therapy*
  • Soft Tissue Neoplasms / drug therapy
  • Soft Tissue Neoplasms / mortality
  • Soft Tissue Neoplasms / therapy*
  • Survival Rate
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / adverse effects
  • Tumor Necrosis Factor-alpha / therapeutic use*

Substances

  • Tumor Necrosis Factor-alpha